...
机译:CD38表达和补体抑制剂影响骨髓瘤的反应和抵抗达拉穆姆治疗
Vrije Univ Amsterdam Med Ctr Canc Ctr Amsterdam Dept Hematol Amsterdam Netherlands;
Janssen Res &
Dev Beerse Belgium;
Univ Med Ctr Utrecht Lab Translat Immunol Utrecht Netherlands;
Vrije Univ Amsterdam Med Ctr Canc Ctr Amsterdam Dept Hematol Amsterdam Netherlands;
Janssen Res &
Dev Spring House PA USA;
Janssen Res &
Dev Spring House PA USA;
Vrije Univ Amsterdam Med Ctr Canc Ctr Amsterdam Dept Hematol Amsterdam Netherlands;
Erasmus MC Canc Inst Dept Hematol Rotterdam Netherlands;
Erasmus MC Canc Inst Dept Hematol Rotterdam Netherlands;
Univ Med Ctr Utrecht Dept Hematol Utrecht Netherlands;
Vrije Univ Amsterdam Med Ctr Canc Ctr Amsterdam Dept Hematol Amsterdam Netherlands;
Janssen Res &
Dev Spring House PA USA;
Univ Med Ctr Utrecht Lab Translat Immunol Utrecht Netherlands;
Vrije Univ Amsterdam Med Ctr Canc Ctr Amsterdam Dept Hematol Amsterdam Netherlands;
Vrije Univ Amsterdam Med Ctr Canc Ctr Amsterdam Dept Hematol Amsterdam Netherlands;
Janssen Res &
Dev Spring House PA USA;
Vrije Univ Amsterdam Med Ctr Canc Ctr Amsterdam Dept Hematol Amsterdam Netherlands;
机译:CD38表达和补体抑制剂影响骨髓瘤的反应和抵抗达拉穆姆治疗
机译:达拉姆拉夫抗性在高级阶段的多发性骨髓瘤患者中频繁频繁,无论CD38表达如何,都与令人沮丧的预后有关
机译:DNA甲基转移酶抑制剂上调CD38蛋白表达,并在多发性骨髓瘤中提高达拉穆巴布疗效
机译:黑色素瘤中BRAF抑制剂抗性的基因表达模型预测了新型组合疗法的药物重新培养候选者
机译:表征人类多发性骨髓瘤细胞系中获得的蛋白酶体抑制剂抗性。
机译:DNA甲基转移酶抑制剂上调CD38蛋白表达并增强daratumumab在多发性骨髓瘤中的疗效
机译:DNA甲基转移酶抑制剂上调CD38蛋白表达,并在多发性骨髓瘤中提高达拉穆巴布疗效